Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy

Raisa Perzova, Elliot Graziano, Swathi Sanghi, Caitlin Welch, Patricia Benz, Lynn Abbott, Danielle Lalone, Jordan Glaser, Thomas Loughran, William Sheremata, Bernard J. Poiesz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Previously, we had shown that although only 8% of patients with large granular lymphocytic leukemia (LGLL) were infected with human T cell lymphoma/leukemia virus (HTLV)-2, almost half had antibodies to HTLV Gag and Env peptides. Herein, we investigated whether this could be due to cross-reactive antibodies to two homologous peptides in the Gag protein of the endogenous retrovirus HTLV-related endogenous sequence-1 (HRES-1). In addition, we had previously shown that patients with HTLV neurodegenerative diseases had increased seroreactivity to homologous HERV-K10 endogenous retrovirus peptides. Hence, in this study we also examined whether these patients had increased seroreactivity to the aforementioned HRES-1 Gag peptides. Sera from 100 volunteer blood donors (VBD), 53 patients with LGLL, 74 subjects with HTLV-1 or 2 infection (58 nonmyelopathy and 16 myelopathy), and 83 patients with multiple sclerosis (MS) were evaluated. The HTLV-positive myelopathy (HAM) patients had a statistically increased prevalence of antibodies to both HRES-1 Gag peptides (81%) vs. the VBD (0%), LGLL patients (13%), and MS patients (1%), and the HTLV-positive nonmyelopathy subjects (21%). The data suggest that cross-reactivity to HRES-1 peptides could be involved in the pathogenesis of HAM. The difference between the VBD and LGLL patients was also statistically significant, also suggesting a possible association in a minority of patients.

Original languageEnglish
Pages (from-to)242-249
Number of pages8
JournalAIDS Research and Human Retroviruses
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Deltaretrovirus
Spinal Cord Diseases
Peptides
Large Granular Lymphocytic Leukemia
Endogenous Retroviruses
Blood Donors
Volunteers
Multiple Sclerosis
Deltaretrovirus Antibodies
gag Gene Products
Adult T Cell Leukemia Lymphoma
Antibodies
Virus Diseases
Neurodegenerative Diseases

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy. / Perzova, Raisa; Graziano, Elliot; Sanghi, Swathi; Welch, Caitlin; Benz, Patricia; Abbott, Lynn; Lalone, Danielle; Glaser, Jordan; Loughran, Thomas; Sheremata, William; Poiesz, Bernard J.

In: AIDS Research and Human Retroviruses, Vol. 31, No. 2, 01.02.2015, p. 242-249.

Research output: Contribution to journalArticle

Perzova, R, Graziano, E, Sanghi, S, Welch, C, Benz, P, Abbott, L, Lalone, D, Glaser, J, Loughran, T, Sheremata, W & Poiesz, BJ 2015, 'Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy', AIDS Research and Human Retroviruses, vol. 31, no. 2, pp. 242-249. https://doi.org/10.1089/aid.2014.0171
Perzova, Raisa ; Graziano, Elliot ; Sanghi, Swathi ; Welch, Caitlin ; Benz, Patricia ; Abbott, Lynn ; Lalone, Danielle ; Glaser, Jordan ; Loughran, Thomas ; Sheremata, William ; Poiesz, Bernard J. / Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy. In: AIDS Research and Human Retroviruses. 2015 ; Vol. 31, No. 2. pp. 242-249.
@article{dad303ca437642329cd1d6c875db5e3c,
title = "Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy",
abstract = "Previously, we had shown that although only 8{\%} of patients with large granular lymphocytic leukemia (LGLL) were infected with human T cell lymphoma/leukemia virus (HTLV)-2, almost half had antibodies to HTLV Gag and Env peptides. Herein, we investigated whether this could be due to cross-reactive antibodies to two homologous peptides in the Gag protein of the endogenous retrovirus HTLV-related endogenous sequence-1 (HRES-1). In addition, we had previously shown that patients with HTLV neurodegenerative diseases had increased seroreactivity to homologous HERV-K10 endogenous retrovirus peptides. Hence, in this study we also examined whether these patients had increased seroreactivity to the aforementioned HRES-1 Gag peptides. Sera from 100 volunteer blood donors (VBD), 53 patients with LGLL, 74 subjects with HTLV-1 or 2 infection (58 nonmyelopathy and 16 myelopathy), and 83 patients with multiple sclerosis (MS) were evaluated. The HTLV-positive myelopathy (HAM) patients had a statistically increased prevalence of antibodies to both HRES-1 Gag peptides (81{\%}) vs. the VBD (0{\%}), LGLL patients (13{\%}), and MS patients (1{\%}), and the HTLV-positive nonmyelopathy subjects (21{\%}). The data suggest that cross-reactivity to HRES-1 peptides could be involved in the pathogenesis of HAM. The difference between the VBD and LGLL patients was also statistically significant, also suggesting a possible association in a minority of patients.",
author = "Raisa Perzova and Elliot Graziano and Swathi Sanghi and Caitlin Welch and Patricia Benz and Lynn Abbott and Danielle Lalone and Jordan Glaser and Thomas Loughran and William Sheremata and Poiesz, {Bernard J.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1089/aid.2014.0171",
language = "English",
volume = "31",
pages = "242--249",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy

AU - Perzova, Raisa

AU - Graziano, Elliot

AU - Sanghi, Swathi

AU - Welch, Caitlin

AU - Benz, Patricia

AU - Abbott, Lynn

AU - Lalone, Danielle

AU - Glaser, Jordan

AU - Loughran, Thomas

AU - Sheremata, William

AU - Poiesz, Bernard J.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Previously, we had shown that although only 8% of patients with large granular lymphocytic leukemia (LGLL) were infected with human T cell lymphoma/leukemia virus (HTLV)-2, almost half had antibodies to HTLV Gag and Env peptides. Herein, we investigated whether this could be due to cross-reactive antibodies to two homologous peptides in the Gag protein of the endogenous retrovirus HTLV-related endogenous sequence-1 (HRES-1). In addition, we had previously shown that patients with HTLV neurodegenerative diseases had increased seroreactivity to homologous HERV-K10 endogenous retrovirus peptides. Hence, in this study we also examined whether these patients had increased seroreactivity to the aforementioned HRES-1 Gag peptides. Sera from 100 volunteer blood donors (VBD), 53 patients with LGLL, 74 subjects with HTLV-1 or 2 infection (58 nonmyelopathy and 16 myelopathy), and 83 patients with multiple sclerosis (MS) were evaluated. The HTLV-positive myelopathy (HAM) patients had a statistically increased prevalence of antibodies to both HRES-1 Gag peptides (81%) vs. the VBD (0%), LGLL patients (13%), and MS patients (1%), and the HTLV-positive nonmyelopathy subjects (21%). The data suggest that cross-reactivity to HRES-1 peptides could be involved in the pathogenesis of HAM. The difference between the VBD and LGLL patients was also statistically significant, also suggesting a possible association in a minority of patients.

AB - Previously, we had shown that although only 8% of patients with large granular lymphocytic leukemia (LGLL) were infected with human T cell lymphoma/leukemia virus (HTLV)-2, almost half had antibodies to HTLV Gag and Env peptides. Herein, we investigated whether this could be due to cross-reactive antibodies to two homologous peptides in the Gag protein of the endogenous retrovirus HTLV-related endogenous sequence-1 (HRES-1). In addition, we had previously shown that patients with HTLV neurodegenerative diseases had increased seroreactivity to homologous HERV-K10 endogenous retrovirus peptides. Hence, in this study we also examined whether these patients had increased seroreactivity to the aforementioned HRES-1 Gag peptides. Sera from 100 volunteer blood donors (VBD), 53 patients with LGLL, 74 subjects with HTLV-1 or 2 infection (58 nonmyelopathy and 16 myelopathy), and 83 patients with multiple sclerosis (MS) were evaluated. The HTLV-positive myelopathy (HAM) patients had a statistically increased prevalence of antibodies to both HRES-1 Gag peptides (81%) vs. the VBD (0%), LGLL patients (13%), and MS patients (1%), and the HTLV-positive nonmyelopathy subjects (21%). The data suggest that cross-reactivity to HRES-1 peptides could be involved in the pathogenesis of HAM. The difference between the VBD and LGLL patients was also statistically significant, also suggesting a possible association in a minority of patients.

UR - http://www.scopus.com/inward/record.url?scp=84923218172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923218172&partnerID=8YFLogxK

U2 - 10.1089/aid.2014.0171

DO - 10.1089/aid.2014.0171

M3 - Article

C2 - 25295378

AN - SCOPUS:84923218172

VL - 31

SP - 242

EP - 249

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -